Form 8-K

HELIX BIOMEDIX, INC.

Dated: September 3, 2008

/s/ R. Stephen Beatty

R. Stephen Beatty

President and Chief Executive Officer

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CDgbszCwQbZK9sag9eSh30sAIl6X+TRKeanxCpY+9vgvq5kSs5Qx6Q0mXKOlqPP6 BKNcE8/Md2qvHSQDYmoT1Q== 0001193125-08-189352.txt : 20080903 0001193125-08-189352.hdr.sgml : 20080903 20080903163852 ACCESSION NUMBER: 0001193125-08-189352 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080827 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20080903 DATE AS OF CHANGE: 20080903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 081054330 BUSINESS ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2008

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

033-20897-D

91-2099117

(State or other jurisdiction

of incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification No.)

22118 20th Avenue SE, Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement.

On August 27, 2008, Helix BioMedix, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Rodan & Fields, LLC (“R+F”). Pursuant to the Agreement, the Company granted to R+F a non-exclusive worldwide license to use the Company’s proprietary Pip3 protease inhibition technology with the Company’s proprietary peptides incorporated into products to be developed by R+F and to market and sell such products in the cosmetic and over-the-counter personal care products markets through R+F’s direct marketing and sales distribution channels and related internet and retail sales distribution channels. In consideration for the license, R+F has agreed to initiate a study for the purpose of validating the benefits of the Company’s Pip3 technology and to pay a royalty fee from the sale of each product unit. The initial term of the Agreement is three years and may be renewed for successive one-year terms thereafter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

-----END PRIVACY-ENHANCED MESSAGE-----